A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope

Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers express a low number of neoantigens; in these cases, ensuring the immunotherapeutic potential of each neoantigen-derived epitope (neoepitope) is crucial. In this study, we discovered that therapeutic vaccines targeting immunodominant major histocompatibility complex (MHC) I-restricted neoepitopes require a conjoined helper epitope in order to induce a cytotoxic, neoepitope-specific CD8+ T-cell response. Furthermore, we show that the universally immunogenic helper epitope P30 can fulfill this requisite helper function. Remarkably, conjoined P30 was able to unveil immune and antitumor responses to subdominant MHC I-restricted neoepitopes that were, otherwise, poorly immunogenic. Together, these data provide key insights into effective neoantigen vaccine design and demonstrate a translatable strategy using a universal helper epitope that can improve therapeutic responses to MHC I-restricted neoepitopes.

Automated summary

This study shows that therapeutic vaccines targeting immunodominant MHC I-restricted neoepitopes require a conjoined helper epitope to induce a cytotoxic CD8+ T-cell response, and the universally immunogenic helper epitope P30 can fulfill this function. Moreover, the conjoined P30 can improve immune and antitumor responses to subdominant MHC I-restricted neoepitopes that are poorly immunogenic. These findings provide insights into effective neoantigen vaccine design and suggest a translational strategy to enhance therapeutic responses to MHC I-restricted neoepitopes.